Lexaria Bioscience LEXX
NASDAQ LEXX
$2.88 -0.21 (-6.80%)
At close: Oct 2, 2026 · 4:00 PM EDT

Lexaria Bioscience (LEXX) Other Accumulated Expenses (2025 - 2026)

Updated

Lexaria Bioscience's Other Accumulated Expenses came in at $400,000 for fiscal Q3 2026 (quarter ended May 31, 2026), up 100.0% from the prior quarter.

Analysis

Lexaria Bioscience (LEXX) Other Accumulated Expenses (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Lexaria Bioscience 3.04 Mn -12.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
May 31, 2026 400,000.00
Feb 28, 2026 200,000.00
Nov 30, 2025 1.50 Mn
API Access

Lexaria Bioscience Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=LEXX&period=max&api_key=YOUR_API_KEY